The funding to keep his drug discovery pursuits alive may not be a problem, as Jasti in December last year sold his profitable contract development and manufacturing services (CDMO) venture Suven Pharmaceuticals to private equity firm Advent International for ₹6,313 crore.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LGnCFth
via IFTTT
0 comments:
Post a Comment